Human clinical trials are showing promising results for Lovaxin C, a live Listeria vaccine, in patients with advanced cervical cancer. Lovaxin C is being developed by Advaxis, a biotechnology company specifically investigating Listeria monocytogenes that have been genetically altered as a means to treat various cancers.
Lovaxin C's active ingredient, attenuated live Listeria, is a type of bacteria that often causes food poisoning. Consequently, the vaccine may be administered with an antibiotic in order to prevent bacterial infection.
Clinical trials have shown that Lovaxin C is safe, and has even shown to help women with advanced cervical cancer. However, all subjects reported Flu-like symptoms, but administering the vaccine in limited doses eased the severity of the symptoms. In addition, discomfort was easily treatable with over-the-counter drugs.
Disclaimer:
The content on this page is not a substitute for professional medical advice. Please contact a physician for information on Lovaxin C.
Lovaxin C Information and News
- Advaxis: Clinical Development: Lovaxin C
- Google News: Lovaxin C
- HealthDay: Experimental Cancer Vaccines Show Promise (April 15, 2008)
- BioPortfolio: Cobra Signs Agreement with Advaxis to Manufacture Lovaxin C Vaccine (October 22, 2007)
- PR Leap: What Women Must Know About Cervical Cancer Vaccines in the News (May 22, 2006)
- Medical News Today: Advaxis Advances Therapeutic Cervical Cancer Vaccine In Effort To Save... (May 9, 2006)
- "The first cancer patients to be treated with an engineered live Listeria vaccine were recently dosed in Advaxis Inc. Phase I/II clinical trial of Lovaxin C, a Listeria-based therapeutic cancer vaccine developed to treat cervical cancer."
- Cancer Compass: Two Leading Biotech Publications Report On Advaxis' Potential... (December 12, 2005)
Lovaxin C Clinical Studies and Research
- PubMed Central Search: Lovaxin C
